A Game-Changer for Colorectal Cancer Detection: Simple Stool Tests Are Transforming Screening

Revolutionary stool tests using artificial intelligence can now detect 90% of colorectal cancers, nearly matching the accuracy of colonoscopies while eliminating the cost and discomfort of invasive procedures. Scientists at the University of Geneva have developed the first detailed catalog of gut bacteria at the subspecies level, creating a breakthrough screening method that could transform how we catch this deadly disease early.

How Do These New Stool Tests Work?

The breakthrough lies in analyzing gut microbiota at an unprecedented level of detail. Instead of looking at broad bacterial species, researchers focused on subspecies—a middle ground that captures meaningful differences in how bacteria function while remaining consistent across different populations. Using machine learning algorithms, scientists can identify specific bacterial patterns that signal the presence of colorectal cancer.

"Instead of relying on the analysis of the various species composing the microbiota, which does not capture all meaningful differences, or of bacterial strains, which vary greatly from one individual to another, we focused on an intermediate level of the microbiota, the subspecies," explains Mirko Trajkovski, professor in the Department of Cell Physiology and Metabolism at the University of Geneva Faculty of Medicine.

What Makes These Tests So Accurate?

The results are striking when compared to existing screening methods. The University of Geneva's AI-powered stool test achieved a 90% detection rate for colorectal cancer, remarkably close to colonoscopy's 94% accuracy. Meanwhile, the FDA-approved ColoSense test demonstrated even higher sensitivity at 94.4% for detecting colorectal cancer and 45.9% for advanced adenomas in a study of 8,920 participants.

These new stool-based tests offer several key advantages over traditional screening:

• Non-invasive Collection: Patients can collect samples at home without the preparation, sedation, or discomfort required for colonoscopy
• Cost-Effective Screening: Stool tests eliminate the need for specialized facilities and medical procedures, making screening more accessible
• High Accuracy Rates: Both RNA-based and microbiome-based tests are showing detection rates that rival or exceed traditional colonoscopy
• Broader Population Reach: The convenience factor could help increase screening rates among people who avoid colonoscopies due to cost or discomfort

Why Is This Timing So Critical?

Colorectal cancer is the second leading cause of cancer death worldwide, yet it's highly treatable when caught early. The Prevent Cancer Foundation's 2025 Early Detection Survey revealed troubling trends: only 51% of U.S. adults 21 and older had routine medical appointments or cancer screenings in the past year, representing a 10-percentage point drop from 2024.

The decline in screening rates makes these innovative stool tests particularly valuable. Among patients with colorectal cancer detected by ColoSense, 47% were 54 years or younger, and the test showed 100% detection rates for cancer in patients aged 45 to 49. This is especially important given the unexplained rise in colorectal cancer cases among young adults.

"The growing number of adults diagnosed with colorectal cancer underscores the urgent need for innovative approaches in screening," said Anjee Davis, president of Fight CRC. The encouraging news from the survey shows that when people learn about early detection benefits, 73% become more likely to schedule routine cancer screenings.

A clinical trial is already being set up with Geneva University Hospitals to determine which cancer stages and lesions can be detected most effectively. The applications extend beyond colorectal cancer, with researchers suggesting the same microbiome analysis method could develop diagnostic tools for a wide range of diseases. As these tests become more widely available, they represent a significant step toward making life-saving cancer screening as simple as a routine stool sample.